Active principle oropharyngeal spray + Active principle immunostimulant taken PO.

Placebo oropharyngeal spray + Active principle immunostimulant taken PO.
Placebo oropharyngeal spray + Placebo taken PO.

Active principle oropharyngeal spray + Placebo taken PO.

Placebo oropharyngeal spray + Placebo taken PO.

COVID

Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.
Intervention 2. Preparation in a solid pharmaceutical presentation for oral administration in a capsule form (inside a small gelatin container), that contains the bioactive compounds that have demonstrated modulation of the inflammatory response recognized at the moment in the immune activation against the virus.

Group A: oropharygeal spray and immunostimulant

Preparation in a liquid solution to be used for oropharyngeal spray, composed of placebo substances of routine use in humans.
Intervention 2. Preparation in a solid pharmaceutical presentation for oral administration in a capsule form (inside a small gelatin container), that contains the bioactive compounds that have demonstrated modulation of the inflammatory response recognized at the moment in the immune activation against the virus.

Group B: Placebo oropharyngeal spray + Active principle immunostimulant

Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.
Intervention 2. Preparation in a solid pharmaceutical presentation for oral administration in a capsule form (inside a small gelatin container), that contains the Placebo compounds

Group C:Active principle oropharyngeal spray + Placebo taken PO

Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.
Intervention 2. Preparation in a solid pharmaceutical presentation for oral administration in a capsule form (inside a small gelatin container), that contains the Placebo compounds

Group D:Placebo oropharyngeal spray + Placebo taken PO

Primary Prevention of Infection by COVID-19 in Health Providers

Scheme of Primary Prevention of Infection by COVID-19, in Health Providers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

Seroconversion of IgM for COVID-19. Result of positive IgM antibodies: A previously scheduled closure visit will be conducted, the trial product will be interrupted if a case is classified as severe-critical, and clinical follow up will be continued as planned. As protocols by the Health Ministry dictate, cases will be confirmed with a PCR-RT test, for the diagnosis of COVID-19. The result of the test will be requested to document the outcome.

Clara Ines Aristizabal

Beatriz H Aristizabal B, MsC immunology, MsC Medical Genetics, PhD Molecular Biolgy, Scientific director of Unidad de Investigación Genética Molecular

Unidad de Investigación Genética Molecular

Universidad de Antioquia

Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in healthcare providers in Medellín-Antioquia. Randomized clinical trial, parallel design, triple-blind, phase II.
Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in healthcare providers in Medellín-Antioquia. Randomized clinical trial, parallel design, triple-blind, phase II.
A four arm RCT is stipulated, in the following manner:
Group A: Active principle spray + Active principle capsules. Group B: Placebo spray + Active principle capsules. Group C: Active principle spray + Placebo capsules. Group D: Placebo spray + Placebo capsules.

Once the participant has given its informed consent, and the research team has verified the fulfillment of the inclusion criteria, the prospect receives a text message, to be directed to the pharmaceutical service. The numbered scheme will be dispensed with the code of the intervention, following the order from the allocation listing, provided by the CTCC. The head of the pharmaceutical service will register the date and time of the first dose. He will provide indications for the use, handling and conservation of the products. Warning signs and symptoms and instructions for communication with the research team to address any concern the subject may have will be reviewed. He will remind the subject to avoid its damage or loss. He will give the participant instructions to return the container and surpluses of the products at the end of the trial (day 30), he will point out that they are for personal use only and that they cannot be shared.

allicin/kaszel

Primary Prevention of Infection by COVID-19 in Health Providers

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo